However, GSK-J4 treatment did not affect the sensitivity of K562 cells to imatinib (Figure 2B), implying that the demethylase activity of KDM6A is dispensable for protection of CML cells against imatinib. The gene discussed is KDM6A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.